| Autor: |
Hinman LM; Novartis Pharmaceuticals Corp., East Hanover, NJ 07939-1080, USA. lois.hinman@novartis.com, Carl KM, Spear BB, Salerno RA, Becker RL, Abbott BM, Kelly JF, Mansfield E, Katz RG, Harper C, Day SP, Pacanowski MA, Pignato W |
| Jazyk: |
angličtina |
| Zdroj: |
Pharmacogenomics [Pharmacogenomics] 2010 Dec; Vol. 11 (12), pp. 1669-75. |
| DOI: |
10.2217/pgs.10.141 |
| Abstrakt: |
At the 5th FDA-Drug Industry Association (DIA) Workshop on 'Pharmacogenomics in Drug Development and Regulatory Decision Making', track four focused on the current thinking and issues in the co-development of therapeutic drugs or biologics, and their companion diagnostic products. Identification and validation of genomic and other biomarkers are becoming important components of drug-development strategies, and recent successes show the power of personalized approaches to change the benefit-risk paradigm for new drugs. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
